Tonix Pharmaceuticals Holding Corp. (TNXP): Price and Financial Metrics


Tonix Pharmaceuticals Holding Corp. (TNXP): $0.37

0.00 (1.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TNXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TNXP Stock Price Chart Interactive Chart >

Price chart for TNXP

TNXP Price/Volume Stats

Current price $0.37 52-week high $14.24
Prev. close $0.37 52-week low $0.36
Day low $0.37 Volume 966,600
Day high $0.38 Avg. volume 4,012,121
50-day MA $0.46 Dividend yield N/A
200-day MA $2.56 Market Cap 21.57M

Tonix Pharmaceuticals Holding Corp. (TNXP) Company Bio


Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS"). The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD").


TNXP Latest News Stream


Event/Time News Detail
Loading, please wait...

TNXP Latest Social Stream


Loading social stream, please wait...

View Full TNXP Social Stream

Latest TNXP News From Around the Web

Below are the latest news stories about TONIX PHARMACEUTICALS HOLDING CORP that investors may wish to consider to help them evaluate TNXP as an investment opportunity.

TNXP: Six Phase 2 or 3 Studies for CNS Programs Expected in the Clinic by 1Q23

By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Up to Six Phase 2 or 3 Studies for CNS Programs Expected in the Clinic by 1Q23 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has built a diverse pipeline that includes development candidates for multiple central nervous system (CNS) diseases, biodefense, and immunology. The company could have up to six Phase 2

Yahoo | December 5, 2022

Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals

Hematopoietic Stem Cell Transplantation (HCT) from Unrelated Donors is a Component of the Treatment Protocol for Several Hematologic Malignancies GvHD Complicates Treatment and Limits the Success of Engraftment after HCT In addition to GvHD, Tonix is Developing TNX-1500 for Prophylaxis of Organ Transplant Rejection and Treatment of Autoimmune Disorders Phase 1 Study of TNX-1500 is Expected to Start in First Half 2023 CHATHAM, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding

Yahoo | December 5, 2022

Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress

TNX-801 is Based on the Sequence of a Natural Isolate of Horsepox and is Believed Closer in Structure to Edward Jenner’s 1798 Vaccine than Modern Vaccinia Virus Vaccines Against Smallpox Live-Virus Vaccine Platform Leverages Tonix’s Expanding Internal Development and Manufacturing Capabilities for Biologics CHATHAM, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chie

Yahoo | December 1, 2022

Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress

Research Being Conducted in Collaboration with Scientists at Columbia University SARS-CoV-2 Variants have Evaded Antibody Therapeutics Previously Granted FDA Emergency Use Authorization, but which are No Longer Recommended for Use by the NIH COVID-19 Guidelines Panel Immunocompromised Individuals, Including Organ Transplant Recipients, are at Increased Risk of Severe COVID-19 and Poor Outcomes Therapeutic Antibody Platform Leverages Tonix’s Expanding Internal Development and Manufacturing Capabi

Yahoo | November 30, 2022

Tonix Pharmaceuticals to Participate in the A.G.P. Biotech Conference

CHATHAM, N.J., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate virtually in the A.G.P. Biotech Conference and host investor meetings. The conference is being held Wednesday, November 30, 2022 – Thursday, December 1, 2022. Investors interested in arranging a meeting with the Company’s management during the conference should contact the conference coordinator or Ian Fr

Yahoo | November 23, 2022

Read More 'TNXP' Stories Here

TNXP Price Returns

1-mo -19.02%
3-mo -63.37%
6-mo -80.83%
1-year -97.41%
3-year -98.81%
5-year -100.00%
YTD -96.77%
2021 -47.01%
2020 -42.31%
2019 -94.68%
2018 -93.62%
2017 -26.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9923 seconds.